Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
REVIEW PAPER
Ocular complications in psoriasis and psoriatic arthritis
1
Clinical Department of Dermatology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
2
Early Arthritis Clinic, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
3
Department of Ophthalmology, Warsaw Medical University, Poland
4
Department of Psychiatry, Combat Stress and Psychotraumatology, Military Institute of Medicine, Warsaw, Poland
These authors had equal contribution to this work
Submission date: 2025-07-14
Final revision date: 2026-01-23
Acceptance date: 2026-02-05
Online publication date: 2026-04-23
Corresponding author
Anna Suchecka
Clinical Department of Dermatology, National Medical Institute of the Ministry of the Interior and Administration, 137 Wołoska St., 02-507 Warsaw, Poland
Clinical Department of Dermatology, National Medical Institute of the Ministry of the Interior and Administration, 137 Wołoska St., 02-507 Warsaw, Poland
KEYWORDS
TOPICS
ABSTRACT
Ophthalmologic symptoms are reported in 10–67% of psoriasis (Ps) cases and affect up to 31% of patients with psoriatic arthritis (PsA). The most common include blepharitis, eyelid involvement, uveitis, dry eye syndrome, conjunctivitis, corneal changes, and cataract. Despite the relatively common eye involvement, these symptoms are often overlooked or inadequately managed. Therefore, dermatologists and rheumatologists should interview patients for eye-related complaints to effectively identify and treat patients with ocular manifestations. In some cases, direct collaboration with ophthalmologists is also necessary for comprehensive patient management. The purpose of this intradisciplinary review is to discuss the most common eye symptoms among Ps and PsA patients, which should be considered as a basis for formulating guidelines for Ps treatment by dermatologists, ophthalmologists, rheumatologists, general practitioners and other specialists. In addition, we propose a simple diagnostic and therapeutic algorithm to facilitate the management of patients with Ps and accompanying symptoms of uveitis.
REFERENCES (78)
1.
Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 (suppl 2): ii18–ii25, DOI: 10.1136/ard.2004.033217.
2.
Petit RG, Cano A, Ortiz A, et al. Psoriasis: from pathogenesis to pharmacological and nano technological based therapeutics. Int J Mol Sci 2021; 22: 4983, DOI: 10.3390/ijms22094983.
3.
Alshobaili HA, Shahzad M, Al Marshood A, et al. Genetic background of psoriasis. Int J Health Sci (Qassim) 2010; 4: 23–29.
4.
Kamiya K, Kishimoto M, Sugai J, et al. Risk factors for the development of psoriasis. Int J Mol Sci 2019; 20: 4347, DOI: 10.3390/ijms20184347.
5.
Dand N, Mahil SK, Capon F, et al. Psoriasis and genetics. Acta Derm Venereol 2020; 100: adv00030, DOI: 10.2340/00015555 3384.
6.
Singh S, Pradhan D, Puri P, et al. Genomic alterations driving psoriasis pathogenesis. Gene 2019; 683: 61–71, DOI: 10.1016/j.gene.2018.09.042.
7.
Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386: 983–994, DOI: 10.1016/S0140 6736(14)61909 7.
8.
Huerta C, Rivero E, Rodríguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559–1565, DOI: 10.1001/archderm.143.12.1559.
9.
Roszkiewicz M, Dopytalska K, Szymańska E, et al. Environmental risk factors and epigenetic alternations in psoriasis. Ann Agric Environ Med 2020; 27: 335–342, DOI: 10.26444/aaem/11210710.
10.
MacDonald A, Burden AD. Psoriasis: advances in pathophysiology and management. Postgrad Med J.2007; 83: 690–697, DOI: 10.1136/pgmj.2007.058448.
11.
Busse K, Liao W. Which psoriasis patients develop psoriatic arthritis? Psoriasis Forum 2010; 16a: 17–25, DOI: 10.1177/247553031016a00403.
12.
Au SC, Yaniv S, Gottlieb AB. Psoriatic eye manifestations. Psoriasis Forum 2011; 17a: 169–179, DOI: 10.1177/247553031117a00301.
13.
Babaie F, Omraninava M, Gorabi AM, et al. Etiopathogenesis of psoriasis from genetic perspective: an updated review. Curr Genomics 2022; 23: 163–174, DOI: 10.2174/1389202923666220322165640.
14.
Zhang XJ, He PP, Wang ZX, et al. Evidence for a major psoriasis susceptibility locus at 6p21 (PSORS1) and a novel candidate region at 4q31 by genome wide scan in Chinese Hans. J Invest Dermatol 2002; 119: 1361–1366, DOI: 10.1046/j.1523 1747.2002.19649.x.
15.
Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun 2015; 64: 66–73, DOI: 10.1016/j.jaut.2015.06.010.
16.
Sokolik R, Gębura K, Iwaszko M, et al. Significance of association of HLA-C and HLA-E with psoriatic arthritis. Hum Immunol 2014; 75: 1188–1191, DOI: 10.1016/j.humimm.2014.10.005.
17.
Schmitt Egenolf M, Boehncke WH, Christophers E, et al. Type I and type II psoriasis show a similar usage of T cell receptor variable regions. J Invest Dermatol 1991; 97: 1053–1056, DOI: 10.1111/1523 1747.ep12376044.
18.
Morizane S, Gallo RL. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol 2012; 39: 225–230, DOI: 10.1111/j.1346 8138.2011.01499.x.
19.
Eldirany SA, Ho M, Bunick CG. Structural basis for how biologic medicines bind their targets in psoriasis therapy. Yale J Biol Med 2020; 93: 19–27.
20.
Fragoulis GE, McInnes IB, Siebert S. JAK inhibitors. New players in the field of immune mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford) 2019; 58 (suppl 1): i43–i54, DOI: 10.1093/rheumatology/key258.
21.
Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol 2020; 182: 840–848, DOI: 10.1111/bjd.18317.
22.
Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010; 130: 1373–1383, DOI: 10.1038/jid.2009.409.
23.
Rajguru JP, Maya D, Kumar D, et al. Update on psoriasis: a review. J Family Med Prim Care 2020; 9: 20–24, DOI: 10.4103/jfmpc.jfmpc_108_19.
24.
Harden JL, Johnson Huang LM, Chamian MF, et al. Humanized anti IFN g (HuZAF) in the treatment of psoriasis. J Allergy Clin Immunol 2015; 135: 553–556, DOI: 10.1016/j.jaci.2014.08.048.
25.
Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL 23-specific mAb) demonstrates clinical and molecular response in patients with moderate to severe psoriasis. J Allergy Clin Immunol 2014; 133: 1032–1040, DOI: 10.1016/j.jaci.2013.12.1045.
26.
Conic RR, Damiani G, Schrom KP, et al. Psoriasis and psoriatic arthritis cardiovascular disease endotypes identified by red blood cell distribution width and mean platelet volume. J Clin Med 2020; 9: 186, DOI: 10.3390/jcm9010162.
27.
Coates LC, Soriano ER, Corp N, et al. GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022; 18: 465–479, DOI: 10.1038/s41584-022-00798-0. Erratum in: Nat Rev Rheumatol 2022; 18: 734, DOI: 10.1038/s41584-022-00861-w.
28.
Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis 2024; 83: 706–719, DOI: 10.1136/ard-2024-225531.
29.
Chowdhury APB, Khurana VK. Ocular findings in psoriasis patients. Int J Contemp Med Res 2017; 4: 634–638.
30.
Murray PI, Rauz S. The eye and inflammatory rheumatic diseases: the eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis. Best Pract Res Clin Rheumatol 2016; 30: 802 825, DOI: 10.1016/j.berh.2017.01.002.
31.
Owczarczyk Saczonek A, Placek W, Wilczek D. Łuszczyca a narząd wzroku [Psoriasis and the eye]. Przegl Dermatol 2013; 100: 269–273 [Article in Polish].
32.
Cruz N, Brandão LS, Cruz S, et al. Ocular manifestations of psoriasis. Arq Bras Oftalmol 2018; 81: 219–225, DOI: 10.5935/0004 2749.20180041.
33.
Kilic B, Dogan U, Parlak AH, et al. Ocular findings in patients with psoriasis. Int J Dermatol 2013; 52: 554–559, DOI: 10.1111/j.1365 4632.2011.05217.x.
34.
Ghalamkarpour F, Baradaran Rafii A, Sadoughi MM, et al. Ocular findings in patients with psoriasis: is it related to the side effects of treatment or to psoriasis itself? A case control study. J Dermatolog Treat 2020; 31: 27–32, DOI: 10.1080/09546634.2019.1566876.
35.
Brinton M, Kossler AL, Patel ZM, et al. Enhanced tearing by electrical stimulation of the anterior ethmoid nerve. Invest Ophthalmol Vis Sci 2017; 58: 2341–2348, DOI: 10.1167/iovs.16 21149.
36.
Maitray ABAS, Shetty SB, Kundu G. Ocular manifestations in psoriasis. IP Int J Ocul Oncol Oculoplasty 2016; 2: 66 70.
37.
Constantin MM, Ciurduc MD, Bucur S, et al. Psoriasis beyond the skin: ophthalmological changes (review). Exp Ther Med 2021; 22: 981, DOI: 10.3892/etm.2021.10034.
38.
Shainhouse T. Ocular manifestations of psoriasis. EC Ophthalmol 2017; 5: 172–176.
39.
Demerdjieva Z, Mazhdrakova I, Tsankov N. Ocular changes in patients with psoriasis. Clin Dermatol 2019; 37: 663–667, DOI: 10.1016/j.clindermatol.2019.03.003.
40.
Campanati A, Neri P, Giuliodori K, et al. Psoriasis beyond the skin surface: a pilot study on the ocular involvement. Int Ophthalmol 2015; 35: 331–340, DOI: 10.1007/s10792 014 9980 4.
41.
Lee CY, Chen HC, Lin HW, et al. Increased risk of keratopathy after psoriasis: a nationwide population based study. PLoS One 2018; 13: e0201285, DOI: 10.1371/journal.pone.0201285.
42.
Lam M, Steen J, Lu JD, Vender R. The incidence and prevalence of uveitis in psoriasis: a systematic review and meta analysis. J Cutan Med Surg 2020; 24: 601–607, DOI: 10.1177/1203475420931322.
43.
Dopytalska K, Sobolewski P, Błaszczak A, et al. Psoriasis in special localizations. Reumatologia 2018; 56: 392–398, DOI: 10.5114/reum.2018.80711.
44.
Rehal B, Modjtahedi BS, Morse LS, et al. Ocular psoriasis. J Am Acad Dermatol 2011; 65: 1202–1212, DOI: 10.1016/j.jaad.2010.10.019.
45.
Rodríguez Ausín P, Antolín Garcia D, Ruano Del Salado M, Hita Antón C. Topical tacrolimus 0.03% for the treatment of ocular psoriasis. Arch Soc Esp Oftalmol 2016; 91: 505–507, DOI: 10.1016/j.oftal.2016.05.022.
46.
Abbouda A, Abicca I, Fabiani C, et al. Psoriasis and psoriatic arthritis related uveitis: different ophthalmological manifestations and ocular inflammation features. Semin Ophthalmol 2017; 32: 715–720, DOI: 10.1080/08820538.2017.1323033.
47.
Aragona E, Rania L, Postorino EI, et al. Tear film and ocular surface assessment in psoriasis. Br J Ophthalmol 2018; 102: 302–308, DOI: 10.1136/bjophthalmol 2017 310955.
48.
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826–850, DOI: 10.1016/j.jaad.2007.12.071.
49.
Ooi KG, Galatowicz G, Calder VL, Lightman SL. Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype? Clin Med Res 2006; 4: 294–308, DOI: 10.3121/cmr.4.4.294.
50.
Sharma S, Kharel R, Parajuli S, Jha S. Rise of biologics in noninfectious uveitis: a retrospective cohort study from Nepal. Ann Med Surg (Lond) 2023; 85: 1486–1489, DOI: 10.1097/MS9.0000000000000546.
51.
Gialouri CG, Evangelatos G, Fragoulis GE. Choosing the appropriate target for the treatment of psoriatic arthritis: TNFa, IL-17, IL-23 or JAK inhibitors? Mediterr J Rheumatol 2022; 33 (Suppl 1): 150–161, DOI: 10.31138/mjr.33.1.150.
52.
Fernández Melón JMF, Hidalgo SMF, Ventura H, et al. Uveitis as the initial clinical manifestation in patients with spondyloarthropathies. J Rheumatol 2004; 31: 524–527.
53.
Haroon M, O’Rourke M, Ramasamy P, et al. A novel evidence based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool). Ann Rheum Dis 2015; 74: 1990–1995, DOI: 10.1136/annrheumdis 2014 206603.
54.
Durrani K, Foster CS. Psoriatic uveitis: a distinct clinical entity? Am J Ophthalmol 2005; 139: 106–110, DOI: 10.1016/j.ajo.2004.07.037.
55.
Dinu A, Bucur S, Olteanu R, et al. Psoriatic arthritis: a permanent new challenge for dermatologists (review). Exp Ther Med 2020; 20: 47–51, DOI: 10.3892/etm.2020.8752.
56.
Biggioggero M, Crotti C, Becciolini A, et al. The management of acute anterior uveitis complicating spondyloarthritis: present and future. Biomed Res Int 2018; 2018: 9460187, DOI: 10.1155/2018/9460187.
57.
Agrawal RV, Murthy S, Sangwan V, Biswas J. Current approach in diagnosis and management of anterior uveitis. Indian J Ophthalmol 2010; 58: 11 19, DOI: 10.4103/0301 4738.58820.
58.
Burek-Michalska A, Turno-Kręcicka A, Grant-Kels JM, Grzybowski A. Biologic therapies for psoriasis and eyes. Clin Dermatol 2023;41: 523–527, DOI: 10.1016/j.clindermatol.2023.08.003.
59.
Balevic SJ, Rabinovich CE. Profile of adalimumab and its potential in the treatment of uveitis. Drug Des Devel Ther 2016; 10: 2997–3003, DOI: 10.2147/DDDT.S94188.
60.
Leal I, Rodrigues FB, Sousa DC, et al. Anti-TNF drugs for chronic uveitis in adults – a systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne) 2019; 6: 104, DOI 10.3389/fmed.2019.00104.
61.
Duica I, Voinea LM, Mitulescu C, et al. The use of biologic therapies in uveitis. Rom J Ophthalmol 2018; 62: 105–113.
62.
Cifuentes-González C, Mejía-Salgado G, Rojas-Carabali W, et al. Biological and therapeutic role of interleukin-6 in non-infectious uveitis: a narrative review. Ocul Immunol Inflamm 2024, DOI: 10.1080/09273948.2024.2408401.
63.
Yang JY, Goldberg D, Sobrin L. Interleukin-6 and macular edema: a review of outcomes with inhibition. Int J Mol Sci 2023; 24: 4676, DOI: 10.3390/ijms24054676.
64.
Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 2017; 36: 191–197, DOI: 10.1007/s10067-016-3506-4.
65.
Cao H, Ma X. Rituximab in the treatment of non-infectious uveitis: a review. J Inflamm Res 2024; 17: 6765–6780, DOI: 10.2147/JIR.S477708.
66.
Pyare R, Shaikh N, Sen A, et al. JAK-STAT inhibitors in noninfectious uveitis – a review. Indian J Ophthalmol 2025; 73: 807–815, DOI: 10.4103/IJO.IJO_61_25.
67.
Weinstein JE, Pepple KL. Cytokines in uveitis. Curr Opin Ophthalmol 2018; 29: 267–274, DOI: 10.1097/ICU.0000000000000492.
68.
Fotiadou C, Lazaridou E. Psoriasis and uveitis: links and risks. Psoriasis (Auckl) 2019; 9: 91–96, DOI: 10.2147/PTT.S179182.
69.
Tungsattayathitthan U, Tesavibul N, Choopong P, et al. Efficacy of golimumab in patients with refractory non-infectious panuveitis. Sci Rep 2024; 14: 2179, DOI: 10.1038/s41598-024-52526-1.
70.
Yamaguchi K, Hayashi T, Takahashi G, et al. Successful certolizumab pegol treatment of chronic anterior uveitis associated with psoriasis vulgaris. Case Rep Ophthalmol 2018; 9: 499–503, DOI: 10.1159/000495655.
71.
Brandt-Jürgens J, Rudwaleit M, Behrens F, et al. Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab. Ther Adv Musculoskelet Dis 2025; 17: 1759720X251340255, DOI: 10.1177/1759720X251340255.
72.
Owczarek W. The role of HLA Cw6 in psoriasis and psoriatic arthritis. Rheumatology 2022; 60: 303–305, DOI: 10.1093/rheumatology/keab526.
73.
Chen L, Tsai TF. HLA Cw6 and psoriasis. Br J Dermatol 2018; 178: 854–862, DOI: 10.1111/bjd.16185.
74.
Köse B, Uzlu D, Erdöl H. Psoriasis and uveitis. Int Ophthalmol 2022; 42: 2303–2310, DOI: 10.1007/s10792 022 02396 7.
75.
Queiro R, Morante I, Cabezas I, Acasuso B. HLA-B27 and psoriatic disease: a modern view of an old relationship. Rheumatology (Oxford) 2016; 55: 221–229, DOI: 10.1093/rheumatology/kev296.
76.
Stern RS. Ocular lens findings in patients treated with PUVA. J Invest Dermatol 1994; 103: 534–538, DOI: 10.1111/1523 1747.ep12393127.
77.
Malanos D, Stern RS. Psoralen plus ultraviolet A does not in-crease the risk of cataracts: a 25 year prospective study. J Am Acad Dermatol 2007; 57: 231–237, DOI: 10.1016/j.jaad.2007.02.028.
78.
Paiva ES, Macaluso DC, Edwards A, Rosenbaum JT. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis 2000; 59: 67 70, DOI: 10.1136/ard.59.1.67.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
